Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer
Satoru Iwasa,Kei Muro,Satoshi Morita,Young Suk Park,Masato Nakamura,Masahito Kotaka,Tomohiro Nishina,Hiroshi Matsuoka,Joong Bae Ahn,Keun‐Wook Lee,Yong Sang Hong,Sae Won Han,Sang‐Hee Cho,Dong‐Sheng Zhang,Wei‐Jia Fang,Li Bai,Xiang‐Lin Yuan,Ying Yuan,Yasuhide Yamada,Junichi Sakamoto,Tae Won Kim
DOI: https://doi.org/10.1111/cas.15092
IF: 5.7
2021-08-31
Cancer Science
Abstract:The phase III AXEPT study demonstrated the non-inferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer (mCRC). We evaluated the associations between the UGT1A1 genotype linked to adverse events - caused by irinotecan - and the efficacy and safety of mXELIRI and FOLFIRI. The UGT1A1 genotype was prospectively determined and patients were categorized into 3 groups according to wild-type (WT, *1/*1), single heterozygous (SH, *28/*1 or *6/*1), and double heterozygous or homozygous (DHH, *28/*28, *6/*6, or *28/*6). Overall survival (OS), progression-free survival, response rate, and safety were assessed. The UGT1A1 genotype was available in all 650 randomized patients (WT: 309 [47.5%]; SH: 291 [44.8%]; DHH: 50 [7.7%]). The median OS was 15.9, 17.7, and 10.6 months in the WT, SH, and DHH groups, respectively, with an adjusted hazard ratio (HR) of 1.53 (95% confidence interval [CI] 1.12–2.09; P = 0.008) for DHH vs. WT or SH. The median OS in the mXELIRI and FOLFIRI arms was 18.1 vs. 14.3 months (HR 0.80; 95% CI 0.62–1.03) in the WT group, 16.3 vs. 18.3 months (HR 1.04; 95% CI 0.79–1.36) in the SH group, and 13.0 vs. 9.1 months (HR 0.71; 95% CI 0.39–1.31) in the DHH group, respectively. mXELIRI with or without bevacizumab could be a standard second-line chemotherapy in terms of efficacy and safety regardless of the UGT1A1 genotype.
oncology